Full-Time

Key Account Manager

Braeburn

Braeburn

201-500 employees

Develops next-generation OUD medications with counseling

No salary listed

Boston, MA, USA

Remote

Regional and national travel up to 50-70%.

Bachelor's, MBA

Category
Sales & Account Management
Required Skills
Sales

Get referred to Braeburn

See people who can refer or advise you

Requirements
  • Bachelor’s degree (BS/BA) required. Advanced business degree a plus
  • 7+ years of pharmaceutical experience with at least 3 years of sales and/or field market access experience in biotech/specialty pharmaceutical/device industries
  • Proven sales or field market access performance as evidenced by market performance reports and recognition awards in Specialty Pharmacy markets
  • In-depth understanding of reimbursement/insurance coverage for physician-administered treatments
  • Proven product launch experience in a highly complicated and competitive environment
  • Experience selling specialty products, in-particular physician-administered products such as implantable or injectable medication technologies in a healthcare setting
  • Ability to work autonomously to find new business opportunities
  • Valid driver’s license and in good standing
  • Experience in a start-up environment a plus
  • Willingness to travel both regionally and nationally. Some territories may require overnight travel up to 50-70%
  • Experience within a complex distribution model including Specialty Pharmacy, Buy & Bill and direct distribution
  • The skills required for a Key Account Manager are Accountability, Adaptability, Business Acumen/Planning, Judgement and Collaboration, Problem Solving, Account Management, Sense of Urgency, Decision Making, and Integrity
Responsibilities
  • Achieve planned Braeburn goals, and patient access to product objectives and other expected performance measures for assigned geography
  • Demonstrate mastery of sales competencies: Business Acumen – Review, analyze and interpret reports / facts and data to plan and execute territory activities that ensure quarterly and annual objectives are met. Develop a deep understanding of assigned territory, including delivery of care, major payers and regulatory environment. Understand industry trends and emerging competition as well as reimbursement patterns and potential implications to patient delivery. Understand state law and policies to execute tactics within a local geography
  • Scientific Knowledge – Mastery of disease state and product information communicated in a compliant manner consistent with the FDA-approved product labeling and REMS program
  • Customer Engagement – Engage with account personnel to prepare for sales call, uncover needs and opportunities, communicate approved solutions, address customer concerns, gain advance/commitment, post call analysis/next steps
  • Using internally approved materials, provide information to help inform physicians and office personnel about access related information for Braeburn’s products
  • Effectively manage and support accounts, which includes ensuring product access and resolving/triage reimbursement issues in a manner that complies with Braeburn policies, processes, and procedures to optimize customer and patient experience
  • Collaborate effectively with all Braeburn cross-functional partners
  • Develop ongoing dialogue with customers to effectively anticipate and adapt to customers’ needs, as well as evolving market challenges and opportunities
  • Exercise sound judgment, and ensure integrity and compliance with all Braeburn policies and Braeburn Code of Conduct
  • Exercise fiscal control of operational expenses

Braeburn focuses on developing next-generation medications for opioid use disorder (OUD) and sells these therapies to healthcare providers, clinics, and patients with the aim of supporting recovery. The medicines are intended to be used together with counseling and support services as part of a comprehensive treatment plan for OUD. The company advances its goal through research, development, and commercialization of therapies, often in partnerships with other healthcare organizations, within the regulated pharmaceutical market. Unlike many generic care models, Braeburn emphasizes a mission-driven approach that combines medical treatments with patient support to help individuals reintegrate into their communities. The overall aim is to reduce the opioid crisis by providing effective, accessible treatments that help patients overcome addiction and rebuild their lives.

Company Size

201-500

Company Stage

Debt Financing

Total Funding

$266M

Headquarters

Washington DC, District of Columbia

Founded

2012

Get referred to Braeburn

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Braeburn presented new BRIXADI data at ASCP on May 28, 2026 and CPDD on June 12, 2026.
  • Camurus and Braeburn entered acquisition talks in September 2025, validating BRIXADI's strategic value.
  • FDA reconsideration of Braeburn's monthly approval issue in May 2026 opens a commercial path.

What critics are saying

  • Braeburn depends almost entirely on BRIXADI; any prescriber backlash hits revenue immediately.
  • Indivior's Sublocade exclusivity fight continues, and FDA delay blocks monthly BRIXADI expansion in 2026.
  • BRIXADI's REMS, injection risks, and restricted distribution limit adoption and preserve clinical friction.

What makes Braeburn unique

  • BRIXADI offers weekly and monthly injectable buprenorphine, unlike daily sublingual OUD therapies.
  • Braeburn owns FDA-approved BRIXADI and controls a long-acting depot platform built with Camurus.
  • The March 2026 MOMs trial showed superior pregnancy abstinence versus sublingual buprenorphine.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Hybrid Work Options

Growth & Insights and Company News

Headcount

6 month growth

3%

1 year growth

3%

2 year growth

2%
New York Globe
Sep 12th, 2025
Swedish Biotech Camurus in Talks to Buy US-Based Braeburn in $1 Billion Opioid Market Bet

Swedish biotech Camurus in talks to buy New York Globe-based Braeburn in $1 billion opioid market bet.

Braeburn
Sep 30th, 2024
Braeburn Debuts Inspiring Docuseries Celebrating Advocates Uplifting Communities to Combat the Opioid Crisis

(PLYMOUTH MEETING, PA - September 30, 2024) - Braeburn Inc. today announced the launch of Reframe and Reclaim: Shaping the Future of Recovery Stories, a mini docuseries on BraeburnRx.com aimed at destigmatizing opioid use disorder (OUD) and celebrating the compelling advocacy of community champions.

We-Ha.com LLC
Jul 6th, 2023
New Principal Named for West Hartford's Braeburn Elementary School

She will take over for Kim Ambroise, who had served as Braeburn’s interim principal since late 2022, following the departure of the former principal, Jeff Sousa, for a superintendent position in New Hartford.

Cision
May 23rd, 2023
Camurus Announces Fda Approval Of Brixadi™ For The Treatment Of Moderate To Severe Opioid Use Disorder

Camurus announces FDA approval of Brixadi™ for the treatment of moderate to severe opioid use disorder. .

Braeburn
Sep 24th, 2021
Braeburn hires Joshua M. Cohen as Chief Medical Officer

Braeburn announces that Joshua M. Cohen, MD, MPH, FAHS has joined the company as Chief Medical Officer.